BioHarvest Authorizes Buyback of Up to 5% of Shares, Citing Undervaluation
BHST is trading near its 52-week low of $1.42 (2.1% above the low).
Summary
BioHarvest's board authorized a normal course issuer bid to repurchase up to 5% of outstanding shares (1,133,392 shares) on Nasdaq. The company argues the market undervalues its Botanical Synthesis platform and VINIA business. CEO Zaki Rakib emphasized the shift toward a CDMO model with multiple high-value molecules nearing commercialization. The buyback signals management confidence and could support the stock, which trades near its 52-week low. The program starts no earlier than five days after this announcement and runs up to 12 months.
At the time of this announcement, BHST was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.9M. The 52-week trading range was $1.42 to $12.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.